Non-Opioid Pain Patch Market Report 2026

The non-opioid pain patch market size has grown steadily in recent years. It will grow from $3.63 billion in 2025 to $3.79 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to opioid dependency concerns, increasing incidence of musculoskeletal disorders, growth in aging population, expansion of retail pharmacy networks, physician preference for localized pain treatment.

The non-opioid pain patch market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising chronic pain prevalence, increased regulatory support for non-opioid therapies, advancements in transdermal drug delivery technology, growing patient awareness of addiction-free treatments, expansion into neuropathic pain indications. Major trends in the forecast period include rising preference for non-addictive pain management, growing adoption of topical and localized therapies, expansion of over-the-counter and prescription hybrid patches, increased demand for chronic pain management solutions, innovation in patch adhesion and drug delivery duration.

The increasing prevalence of chronic pain is expected to drive the growth of the non-opioid pain patch market in the coming years. Chronic pain is defined as persistent or severe pain that lasts for a prolonged duration or occurs alongside another medical condition. Non-opioid pain patches are commonly used to manage mild to moderate pain and to treat conditions such as headaches, muscle pain, arthritis, back pain, and other pain-related disorders. For example, in November 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency, approximately 24.3% of adults experienced chronic pain in 2023, with 8.5% - representing about one-third of those affected - reporting high-impact chronic pain, and a higher prevalence observed among women compared to men. Therefore, the growing prevalence of chronic pain is fueling the expansion of the non-opioid pain patch market.

Key companies operating in the non-opioid pain patch market are focusing on the development of innovative products, including genetically validated target medicines. Genetically validated target medicine involves creating therapies that act on biological pathways strongly associated with disease, supported by robust genetic evidence, which helps improve treatment efficacy while minimizing side effects. For instance, in February 2024, Latigo Biotherapeutics Inc., a US-based biotechnology company, introduced LTG-001, a selective inhibitor of the Nav1.8 sodium channel that is mainly expressed in peripheral nerve cells. By specifically targeting this channel, LTG-001 is designed to block pain signals at their origin, potentially delivering effective pain relief without impacting the central nervous system. Results from Phase 1 clinical trials showed that LTG-001 achieved a Tmax of approximately 1.5 hours, indicating a rapid onset of pain relief, which is particularly beneficial for managing both acute and chronic pain. Additionally, LTG-001 is formulated for oral administration, offering greater convenience and potentially improved patient compliance compared to injectable or topical therapies.

In January 2024, Heron Therapeutics, a US-based biotechnology company specializing in non-opioid pain medications, entered into a partnership with CrossLink Life Sciences. The collaboration aims to broaden the sales network for ZYNRELEF, a pain management solution used in orthopedic surgeries, across the United States. This partnership is intended to boost product adoption, enhance accessibility, and improve post-operative pain management for a wider patient population. CrossLink Life Sciences is a US-based private distributor of orthopedic, spine, and sports medicine devices.

Major companies operating in the non-opioid pain patch market are Hisamitsu Pharmaceutical Co. Inc., Teikoku Pharma USA Inc., Noven Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., Grünenthal GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Iroko Pharmaceuticals LLC, Scilex Pharmaceuticals Inc., Zosano Pharma Corporation, Adynxx Inc., BioElectronics Corporation, NeuroMetrix Inc., Virpax Pharmaceuticals Inc., Novartis AG, DURECT Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc.

North America was the largest region in the non-opioid pain patch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in the non-opioid pain patch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-opioid pain patch market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the non-opioid pain patch market by increasing costs for imported active pharmaceutical ingredients, medical-grade adhesives, and specialized patch manufacturing materials, thereby impacting overall production economics. These cost pressures are most evident in lidocaine and diclofenac patch segments and in regions reliant on cross-border pharmaceutical supply chains, particularly Asia-Pacific and parts of Europe. Distribution channels such as hospital and retail pharmacies face pricing adjustments due to higher procurement costs. However, tariffs have also encouraged manufacturers to localize production, strengthen domestic supply chains, and invest in process optimization, supporting long-term market resilience.

The non-opioid pain patch market research report is one of a series of new reports that provides non-opioid pain patch market statistics, including non-opioid pain patch industry global market size, regional shares, competitors with a non-opioid pain patch market share, detailed non-opioid pain patch market segments, market trends and opportunities, and any further data you may need to thrive in the non-opioid pain patch industry. This non-opioid pain patch market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-opioid pain patches are topical pain management treatments that are non-opioid, non-systemic, and regarded as the only option offering prescription-strength relief. They deliver non-addictive medication directly to the site of pain through the skin, providing effective pain control while reducing the risk of addiction and the side effects associated with opioid use. These patches are commonly used to alleviate mild to moderate pain.

The key types of non-opioid pain patches include lidocaine patches, diclofenac patches, capsaicin patches, ketoprofen patches, and others. Lidocaine patches are transdermal patches with analgesic properties that contain the synthetic amide-type anesthetic lidocaine in a 5 percent aqueous base solution and are used to help relieve itching and pain associated with certain skin conditions. These patches are distributed through hospital pharmacies, retail pharmacies, and other channels for the treatment of various conditions, including musculoskeletal pain and neuropathic pain.

The non-opioid pain patch market consists of sales of aspirin, ibuprofen, and acetaminophen patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.